ArticleBMJ open respiratory research2026
Innovative Inflammatory Burden Index for identification of high mortality risk in patients with pulmonary embolism: a large retrospective cohort study.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic significance of systemic inflammation in pulmonary embolism (PE) remains unclear. This study aimed to evaluate the predictive value of a novel Inflammatory Burden Index (IBI) for long-term mortality in patients with acute PE.
methodsA total of 1642 patients with acute PE were retrospectively analysed. The optimal cut-off for IBI was determined using maximally selected rank statistics. The association between high IBI and all-cause mortality was assessed using multivariable Cox proportional hazards models. The predictive performance of IBI and its individual components was compared using time-dependent receiver operating characteristic (ROC) curves. Variable importance for mortality prediction was further evaluated using random survival forest (RSF) analysis.
resultsDuring a median follow-up of 41.2 months, 262 patients (16.0%) died. High IBI was independently associated with increased risk of all-cause mortality (adjusted HR 2.33, 95% CI 1.78 to 3.04; p<0.001). Time-dependent ROC analysis demonstrated that IBI provided superior prognostic accuracy for mortality, with area under the curve (AUC) values of 0.73, 0.74 and 0.75 at 1, 3 and 5 years, respectively, which were higher than those of C-reactive protein, neutrophil count and lymphocyte count. Addition of IBI to the basic clinical model significantly improved the AUC at all time points. RSF analysis confirmed that IBI was the most important inflammatory predictor of long-term mortality.
conclusionsThe IBI is a robust and independent predictor of long-term mortality in patients with acute PE and offers incremental prognostic value beyond conventional risk factors. Incorporating IBI into clinical risk stratification may improve patient management and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.